Spotlight Innovation Inc (STLT) 0.3500 $STLT
Spotlight Innovation Achieves Key Laboratory Benchmark for Its Immunoplex Immunotherapy Cancer Vaccine Technology
Marketwired - Tue Apr 19, 7:30AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announced today that its proprietary Immunoplex(TM) epitope tag, which has previously been demonstrated to be stable, scalable, and producible in accordance with Good Manufacturing Practice (GMP), has now been demonstrated, in laboratory cell line models, to successfully attach to tumor cells in a consistent and reproducible manner. The epitope tag is used in conjunction with a universal antibody to create an immune complex vaccine to target a broad range of cancer and infectious disease indications.
Spotlight Innovation Enters Into Research Agreement With the University of Alabama at Birmingham to Study Efficacy of Immunoplex Immunotherapy Technology for Metastatic Breast Cancer
Marketwired - Wed Mar 16, 7:30AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) has entered into a Research Agreement with the University of Alabama at Birmingham (UAB) to conduct studies to validate the efficacy of Spotlight Innovation's Immunoplex(TM) immunotherapy platform technology for metastatic breast cancer in mouse models. These pre-clinical studies are anticipated to take approximately six months and are intended to validate significant and highly favorable prior test data. The data will be submitted as part of an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration. Lyse A. Norian, PhD, is the Principal Investigator. Dr. Norian conducted the original studies during her tenure at the University of Iowa.
Spotlight Innovation Inc. Updates Its Company Overview for Prospective Buyers of Its Shares, Investors and Current Shareholders
Marketwired - Thu Feb 04, 7:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) on February 3, 2016, filed a Form 8-K containing a Company Overview presentation it plans to present to prospective buyers of its shares, investors and current shareholders. The Company Overview presentation can be found on the Company's website at www.spotlightinnovation.com/investors.
Spotlight Innovation Inc. Engages Renowned Oncologist Prof. David Khayat as Principal Investigator for Its European Phase I Clinical Study for Crotoxin
Marketwired - Thu Jan 28, 7:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) has retained noted French oncologist David Khayat, MD, PhD, FASCO, as the Principal Investigator for a European Phase I dose escalation safety study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. The clinical study will be conducted at Pitie-Salpetriere Hospital in Paris.
Spotlight Innovation Inc. Engages WithumSmith+Brown, PC as Its New Auditor
Marketwired - Wed Jan 20, 7:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that following a search and an evaluation period, it has engaged WithumSmith+Brown, PC as its new independent registered public accounting firm. WithumSmith+Brown, PC is a full-service accounting and consulting firm with fifteen offices in the U.S. and other locations. WithumSmith+Brown, PC replaces GBH CPAs, PC as the Company's auditor. The Company had no disagreements with GBH CPAs, PC on any matters.
Spotlight Innovation Subsidiary CDT Veterinary Therapeutics to Commercialize Crotalin as Cancer Therapeutic for Veterinary Market
Marketwired - Thu Dec 03, 7:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that it has formed CDT Veterinary Therapeutics, Inc., a subsidiary company to develop cancer therapeutics for the veterinary market. CDT Veterinary Therapeutics is Spotlight Innovation's third subsidiary company, joining Celtic Biotech and Memcine Pharmaceuticals.
Spotlight Innovation to Present at LD MICRO Main Event Investor Conference on Wednesday, December 2, 2015
Marketwired - Wed Nov 25, 7:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that President and CEO Christopher Grunewald will present at the LD MICRO Main Event Investor Conference on Wednesday, December 2, 2015 at 5:00pm Pacific Standard Time. The conference will take place from December 1-3, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
SeeThruEquity Initiates Coverage on Spotlight Innovation Inc. (OTCQB: STLT) with a Price Target of $1.65
ACCESSWIRE - Thu Nov 19, 8:01AM CST
NEW YORK, NY / ACCESSWIRE / November 19, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Spotlight Innovation Inc.(OTCQB: STLT) with a Price Target of $1.65.
Spotlight Innovation Announces Appointment of Bill Pim as New Chief Financial Officer
Marketwired - Thu Nov 12, 11:39AM CST
Spotlight Innovation Inc. (OTCQB: STLT) today announced that effective November 6, 2015, the board of directors has named Bill Pim, CPA, Chief Financial Officer of the Company. Mr. Pim, 61, has held senior financial positions at companies including: the West Des Moines, IA-based not-for-profit Iowa Foundation for Medical Care (now Telligen); Iowa Renewable Energy, located in Washington, IA; the North Liberty, IA-based Heartland Express transportation firm; and LearningRx franchise locations in Des Moines, IA area. He began his career at the Atlanta, Georgia accounting firm of Thompson and Reed. Mr. Pim holds a Bachelor of Science degree from the University of Iowa, and completed undergraduate coursework in Accounting and graduate MBA coursework at Georgia State University in Atlanta, GA.
HTLD: 18.67 (+0.22)
Spotlight Innovation Subsidiary Memcine Pharmaceuticals Signs Lease for Laboratory Facilities at The BioVentures Center Located at The University of Iowa Research Park
Marketwired - Thu Sep 10, 7:01AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Memcine Pharmaceuticals has signed a lease for use of a wet laboratory at the Coralville, IA-based BioVentures Center located at The University of Iowa Research Park. The lease provides for access to additional shared bioscience and translational medical research facilities.
Spotlight Innovation Subsidiary Celtic Biotech Retains Exclusive License for Use of Crotamine as Cancer Imaging, Gene Therapy Technology From Instituto Butantan
Marketwired - Wed Sep 09, 7:02AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech has entered into an exclusive patent license agreement, applicable to North America, with Sao Paulo, Brazil-based Instituto Butantan for the use of Crotamine, a neurotoxin derived from the venom of the South American rattlesnake Crotalus durissus, as a potential imaging agent for cancer and gene therapy delivery vector.
Spotlight Innovation CEO to Speak at BioNetwork West Partnering Summit October 26-28, 2015
Marketwired - Fri Aug 14, 12:09PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that its CEO Cristopher Grunewald is a scheduled speaker at the BioNetwork West Partnering Summit to be held at the Ritz-Carlton, Laguna Niguel, CA, October 26th through the 28th, 2015.
Spotlight Innovation Engages DAK Capital to Provide Merger and Acquisition Advisory Services
Marketwired - Thu Jul 16, 12:02PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has engaged Rochelle Park, NJ-based DAK Capital, LLC, to provide strategic investment banking advisory services, including merger and acquisition assistance. DAK Capital, a boutique investment bank, provides a broad spectrum of investment advisory services to its middle market clients. Managing Director Jeffrey M. Gold will act as lead banker.
Spotlight Innovation Retains DresnerAllenCaron as Its Investor Relations Firm
Marketwired - Thu Jun 18, 10:51AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has retained DresnerAllenCaron as its investor relations firm. DresnerAllenCaron will design and execute investor relations programs to broaden awareness and visibility of Spotlight Innovation within the investment community, and the business and financial media.
Spotlight Innovation Completes Acquisition of Memcine Pharmaceuticals
Marketwired - Mon Jun 08, 9:45AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it completed the acquisition of a majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex(TM) vaccine platform technology, which is designed to use the body's own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response. Memcine Pharmaceuticals has a licensing agreement for its technologies with the University of Iowa.
Spotlight Innovation Subsidiary Celtic Biotech Retains the FreeMind Group to Identify, Prepare, and File for Research and Development Grant Opportunities
Marketwired - Tue Jun 02, 2:31PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that FreeMind Group LLC has been retained by its subsidiary Celtic Biotech Iowa, Inc. to identify grant and contract funding opportunities from such agencies as the National Institutes of Health (NIH), Department of Defense (DoD) and Private Foundations, and to prepare and file grant applications for relevant opportunities. FreeMind Group's expertise in applying for grants and contracts extends throughout every government mechanism as well as private foundations open to funding the life sciences.
ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
Marketwired - Wed May 20, 11:40AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that ImmunoClin Ltd. will act as its Contract Research Organization for its subsidiary Celtic Biotech Iowa, Inc.'s Part II of its Phase I clinical trial, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd. (a subsidiary of ImmunoClin Corporation, IMCL) will manage and coordinate all aspects of the clinical trial on behalf of Celtic Biotech including protocol preparation, monitoring, project management, and regulatory reporting.
Spotlight Innovation Becomes Member of Iowa Biotechnology Association
Marketwired - Tue May 12, 12:19PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has become a member of the Iowa Biotechnology Association. The Association was founded to unify Iowa's bioscience industry, academic research institutions and economic development organizations, and to foster a strong business and research climate that attracts and retains bioscience talent, companies and funding.
Spotlight Innovation Closes $2.5 Million Financing
Marketwired - Tue Apr 28, 12:05PM CDT
Spotlight Innovation Inc. (the "Company"
(OTCQB: STLT) announces that it has closed on an unsecured convertible promissory note in the gross principal amount of $2,500,000, exclusive of certain fees. The Note has a maturity date of March 27, 2020, and bears interest at the rate of Prime plus five percent (5%) during the first 36 months, increasing to an interest of Prime plus six percent (6%) for the remaining 24 months. The Note is convertible into shares of common stock of the Company at a price of $1.50 per share.
Spotlight Innovation Completes Private Placement Offering of $500,000
Marketwired - Tue Apr 21, 1:25PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces the completion of a $500,000 private placement offering consisting of shares of common stock and warrants.
Spotlight Innovation Achieves Key Laboratory Benchmark for Its Immunoplex Immunotherapy Cancer Vaccine Technology
Marketwired - Tue Apr 19, 7:30AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announced today that its proprietary Immunoplex(TM) epitope tag, which has previously been demonstrated to be stable, scalable, and producible in accordance with Good Manufacturing Practice (GMP), has now been demonstrated, in laboratory cell line models, to successfully attach to tumor cells in a consistent and reproducible manner. The epitope tag is used in conjunction with a universal antibody to create an immune complex vaccine to target a broad range of cancer and infectious disease indications.
Spotlight Innovation Enters Into Research Agreement With the University of Alabama at Birmingham to Study Efficacy of Immunoplex Immunotherapy Technology for Metastatic Breast Cancer
Marketwired - Wed Mar 16, 7:30AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) has entered into a Research Agreement with the University of Alabama at Birmingham (UAB) to conduct studies to validate the efficacy of Spotlight Innovation's Immunoplex(TM) immunotherapy platform technology for metastatic breast cancer in mouse models. These pre-clinical studies are anticipated to take approximately six months and are intended to validate significant and highly favorable prior test data. The data will be submitted as part of an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration. Lyse A. Norian, PhD, is the Principal Investigator. Dr. Norian conducted the original studies during her tenure at the University of Iowa.
Spotlight Innovation Inc. Updates Its Company Overview for Prospective Buyers of Its Shares, Investors and Current Shareholders
Marketwired - Thu Feb 04, 7:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) on February 3, 2016, filed a Form 8-K containing a Company Overview presentation it plans to present to prospective buyers of its shares, investors and current shareholders. The Company Overview presentation can be found on the Company's website at www.spotlightinnovation.com/investors.
Spotlight Innovation Inc. Engages Renowned Oncologist Prof. David Khayat as Principal Investigator for Its European Phase I Clinical Study for Crotoxin
Marketwired - Thu Jan 28, 7:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) has retained noted French oncologist David Khayat, MD, PhD, FASCO, as the Principal Investigator for a European Phase I dose escalation safety study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. The clinical study will be conducted at Pitie-Salpetriere Hospital in Paris.
Spotlight Innovation Inc. Engages WithumSmith+Brown, PC as Its New Auditor
Marketwired - Wed Jan 20, 7:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that following a search and an evaluation period, it has engaged WithumSmith+Brown, PC as its new independent registered public accounting firm. WithumSmith+Brown, PC is a full-service accounting and consulting firm with fifteen offices in the U.S. and other locations. WithumSmith+Brown, PC replaces GBH CPAs, PC as the Company's auditor. The Company had no disagreements with GBH CPAs, PC on any matters.
Spotlight Innovation Subsidiary CDT Veterinary Therapeutics to Commercialize Crotalin as Cancer Therapeutic for Veterinary Market
Marketwired - Thu Dec 03, 7:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that it has formed CDT Veterinary Therapeutics, Inc., a subsidiary company to develop cancer therapeutics for the veterinary market. CDT Veterinary Therapeutics is Spotlight Innovation's third subsidiary company, joining Celtic Biotech and Memcine Pharmaceuticals.
Spotlight Innovation to Present at LD MICRO Main Event Investor Conference on Wednesday, December 2, 2015
Marketwired - Wed Nov 25, 7:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that President and CEO Christopher Grunewald will present at the LD MICRO Main Event Investor Conference on Wednesday, December 2, 2015 at 5:00pm Pacific Standard Time. The conference will take place from December 1-3, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
SeeThruEquity Initiates Coverage on Spotlight Innovation Inc. (OTCQB: STLT) with a Price Target of $1.65
ACCESSWIRE - Thu Nov 19, 8:01AM CST
NEW YORK, NY / ACCESSWIRE / November 19, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Spotlight Innovation Inc.(OTCQB: STLT) with a Price Target of $1.65.
Spotlight Innovation Announces Appointment of Bill Pim as New Chief Financial Officer
Marketwired - Thu Nov 12, 11:39AM CST
Spotlight Innovation Inc. (OTCQB: STLT) today announced that effective November 6, 2015, the board of directors has named Bill Pim, CPA, Chief Financial Officer of the Company. Mr. Pim, 61, has held senior financial positions at companies including: the West Des Moines, IA-based not-for-profit Iowa Foundation for Medical Care (now Telligen); Iowa Renewable Energy, located in Washington, IA; the North Liberty, IA-based Heartland Express transportation firm; and LearningRx franchise locations in Des Moines, IA area. He began his career at the Atlanta, Georgia accounting firm of Thompson and Reed. Mr. Pim holds a Bachelor of Science degree from the University of Iowa, and completed undergraduate coursework in Accounting and graduate MBA coursework at Georgia State University in Atlanta, GA.
HTLD: 18.67 (+0.22)
Spotlight Innovation Subsidiary Memcine Pharmaceuticals Signs Lease for Laboratory Facilities at The BioVentures Center Located at The University of Iowa Research Park
Marketwired - Thu Sep 10, 7:01AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Memcine Pharmaceuticals has signed a lease for use of a wet laboratory at the Coralville, IA-based BioVentures Center located at The University of Iowa Research Park. The lease provides for access to additional shared bioscience and translational medical research facilities.
Spotlight Innovation Subsidiary Celtic Biotech Retains Exclusive License for Use of Crotamine as Cancer Imaging, Gene Therapy Technology From Instituto Butantan
Marketwired - Wed Sep 09, 7:02AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech has entered into an exclusive patent license agreement, applicable to North America, with Sao Paulo, Brazil-based Instituto Butantan for the use of Crotamine, a neurotoxin derived from the venom of the South American rattlesnake Crotalus durissus, as a potential imaging agent for cancer and gene therapy delivery vector.
Spotlight Innovation CEO to Speak at BioNetwork West Partnering Summit October 26-28, 2015
Marketwired - Fri Aug 14, 12:09PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that its CEO Cristopher Grunewald is a scheduled speaker at the BioNetwork West Partnering Summit to be held at the Ritz-Carlton, Laguna Niguel, CA, October 26th through the 28th, 2015.
Spotlight Innovation Engages DAK Capital to Provide Merger and Acquisition Advisory Services
Marketwired - Thu Jul 16, 12:02PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has engaged Rochelle Park, NJ-based DAK Capital, LLC, to provide strategic investment banking advisory services, including merger and acquisition assistance. DAK Capital, a boutique investment bank, provides a broad spectrum of investment advisory services to its middle market clients. Managing Director Jeffrey M. Gold will act as lead banker.
Spotlight Innovation Retains DresnerAllenCaron as Its Investor Relations Firm
Marketwired - Thu Jun 18, 10:51AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has retained DresnerAllenCaron as its investor relations firm. DresnerAllenCaron will design and execute investor relations programs to broaden awareness and visibility of Spotlight Innovation within the investment community, and the business and financial media.
Spotlight Innovation Completes Acquisition of Memcine Pharmaceuticals
Marketwired - Mon Jun 08, 9:45AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it completed the acquisition of a majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex(TM) vaccine platform technology, which is designed to use the body's own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response. Memcine Pharmaceuticals has a licensing agreement for its technologies with the University of Iowa.
Spotlight Innovation Subsidiary Celtic Biotech Retains the FreeMind Group to Identify, Prepare, and File for Research and Development Grant Opportunities
Marketwired - Tue Jun 02, 2:31PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that FreeMind Group LLC has been retained by its subsidiary Celtic Biotech Iowa, Inc. to identify grant and contract funding opportunities from such agencies as the National Institutes of Health (NIH), Department of Defense (DoD) and Private Foundations, and to prepare and file grant applications for relevant opportunities. FreeMind Group's expertise in applying for grants and contracts extends throughout every government mechanism as well as private foundations open to funding the life sciences.
ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
Marketwired - Wed May 20, 11:40AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that ImmunoClin Ltd. will act as its Contract Research Organization for its subsidiary Celtic Biotech Iowa, Inc.'s Part II of its Phase I clinical trial, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd. (a subsidiary of ImmunoClin Corporation, IMCL) will manage and coordinate all aspects of the clinical trial on behalf of Celtic Biotech including protocol preparation, monitoring, project management, and regulatory reporting.
Spotlight Innovation Becomes Member of Iowa Biotechnology Association
Marketwired - Tue May 12, 12:19PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that it has become a member of the Iowa Biotechnology Association. The Association was founded to unify Iowa's bioscience industry, academic research institutions and economic development organizations, and to foster a strong business and research climate that attracts and retains bioscience talent, companies and funding.
Spotlight Innovation Closes $2.5 Million Financing
Marketwired - Tue Apr 28, 12:05PM CDT
Spotlight Innovation Inc. (the "Company"
(OTCQB: STLT) announces that it has closed on an unsecured convertible promissory note in the gross principal amount of $2,500,000, exclusive of certain fees. The Note has a maturity date of March 27, 2020, and bears interest at the rate of Prime plus five percent (5%) during the first 36 months, increasing to an interest of Prime plus six percent (6%) for the remaining 24 months. The Note is convertible into shares of common stock of the Company at a price of $1.50 per share. Spotlight Innovation Completes Private Placement Offering of $500,000
Marketwired - Tue Apr 21, 1:25PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces the completion of a $500,000 private placement offering consisting of shares of common stock and warrants.
